Anup Kasi
University of Kansas Medical Center · The University of Kansas Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anup Kasi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:50 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07174453 · Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care ImmunotherapiesUniversity of Kansas Medical Center · recruiting · Solid Tumor Malignancies · principal investigator
- Ph1/Ph2NCT06736717 · Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic CancerUniversity of Kansas Medical Center · active not recruiting · Pancreatic Cancer · principal investigator
- Ph2NCT05638698 · Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic CancerUniversity of Kansas Medical Center · active not recruiting · Pancreas Cancer · principal investigator
- Ph1/Ph2NCT05121038 · CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without PanitumumabAnup Kasi · unknown · Colon Cancer, Pancreas Cancer, Digestive Cancer · principal investigator
- Ph2NCT03553004 · Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 TrialUniversity of Kansas Medical Center · unknown · Pancreatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:50 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.J Clin Oncol · 2020451 citationsRCR 18.9
- A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.Clin Cancer Res · 2020275 citationsRCR 11.8
- 50 citationsRCR 5.1
- 49 citationsRCR 5.5
- Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.Lancet Respir Med · 202549 citationsRCR 15.9
- Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.J Clin Oncol · 202538 citationsRCR 8.1
- Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.Cell Rep Med · 202336 citationsRCR 2.3
- Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.J Clin Oncol · 202531 citationsRCR 5.9
- Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.N Engl J Med · 202624 citationsRCR 12.0
- 21 citationsRCR 1.3